Stay updated on Pembrolizumab with BCG in HR NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab with BCG in HR NMIBC Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for the pembrolizumab-plus-BCG study in high-risk non-muscle invasive bladder cancer is available, with detailed study design, participant eligibility, outcome measures, and site information.SummaryDifference100%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe site revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner announces NIH’s transition-related terminology update, noting that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check34 days agoChange DetectedThe site’s footer revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe site revision label in the footer changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden message, replacing the study details and navigation. This indicates restricted access to the content.SummaryDifference19%

Stay in the know with updates to Pembrolizumab with BCG in HR NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.